Sol-Gel Technologies Ltd. NCM · SLGL
Price alert —
Sign in to get a one-time email the moment SLGL crosses your price. Free accounts included.
Sign in / create a free accountSol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally.
SLGL last traded at $84.30, down 6.1% on the day; that's in the upper part of its 52-week range ($48.26–$97.97). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.
The next scheduled earnings report (2026-08-21) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.
A quick snapshot built from the data on this page — not investment advice. Always do your own research.
Price is stretched well above its normal range — a standard stretch that often pulls back toward normal.
- · Aligned with breakout up (strong tailwind)
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC2 upper stretch — standard mean-reversion tier
- · RSI hook from overbought (59)
- · Stochastic bear cross in overbought
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Our cash-flow model pegs fair value near $16.63 (fair range $2–$18); today's price sits 370% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.
- ✓ More cash than debt
- ✓ Quick ratio 8.88 (antifragile)
- ✓ Current ratio 4.37 (antifragile)
- ✓ Debt/equity 0.31 (antifragile)
- ⚠ Negative retained earnings
Price implies ~77% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
SLGL is a $276 million company.
Earnings
See more →- Last reported
- 2026-05-28
- EPS (act / est)
- -1.31 / -2.86
- Surprise
- +54.2%
- Next report
- 2026-05-01
About
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical …